Follow us

Leading international law firm Herbert Smith Freehills has advised Goldman Sachs and China International Capital Corporation as joint sponsors and underwriters of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (02315.HK)'s listing on the Main Board of the Hong Kong Stock Exchange.

Biocytogen listed on 1 September 2022. The company focuses on biopharmaceutical research and development, pre-clinical research services and antibody development.

"We are delighted to have worked with Biocytogen, one of the leading biopharmaceutical specialists, on its successful listing on the Hong Kong Stock Exchange," said Hong Kong partner Matt Emsley. "We congratulate the company and the joint sponsors on this successful IPO."

Herbert Smith Freehills has advised on a number of biotech listings since the Hong Kong Stock Exchange introduced its new regime for biotech listings in 2018, including those of Rainmed Medical Limited (02297.HK), Lepu Biopharma (02157.HK), Shanghai Bio-heart (02185.HK), Abbisko Cayman Limited (02256.HK), Acotec Scientific Holdings Limited (06669.HK), Shanghai HeartCare Medical Technology (06609.HK), Brii Biosciences (02137.HK), CARsgen Therapeutics (02171.HK), Antengene Corporation Limited (06996.HK), Peijia Medical (09996.HK), SinoMab BioScience Limited (03681.HK), TOT BIOPHARM (01875.HK) and Shanghai Junshi Biosciences (01877.HK).

"We have a proven record of advising Chinese companies seeking listings overseas, and we look forward to continuing to support issuers and sponsors on their fundraising activities," said Herbert Smith Freehills Kewei join operation partner Stanley Xie.

"Our capital markets offering captures client needs in multiple sectors and jurisdictions," said Hong Kong senior registered foreign lawyer Jin Kong. "In past three years, we have advised over 20 Chinese companies from healthcare, TMT and manufacturing sectors to list in Hong Kong and beyond."

Partners Matt, Stanley and Jin jointly led the team advising the joint sponsors, assisted by senior associate Jaime Fong, associates Cyrus Wong, Kristina Li, Sean Ji, Haiyun Chen and Ting Wang and legal assistant Han Ye. Registered foreign lawyer Ariel Lin, legal manager Hilary Chong, trainee solicitor Colbert Hung, and legal assistants Jessica Lu and Tiffany Chan also provided support.

Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation’s Alternative Legal Services business to provide high-efficiency solutions for verification and other document-intensive processes during the listing, assisted by senior legal analyst Jean Zhou.

全球领先的律师事务所史密夫斐尔于百奥赛图(北京)医药科技股份有限公司(02315.HK)在香港联交所主板上市的项目中担任联席保荐人和承销商高盛和中金公司的律师并提供法律服务。

百奥赛图的股份于2022年9月1日开始在香港联交所交易。公司专注于生物医药研发、临床前研究服务和抗体发现业务。

史密夫斐尔香港办公室合伙人艾迈修(Matt Emsley)表示:“百奥赛图是生物医药领域的领先公司之一,我们非常荣幸为其在联交所上市提供助力。我们衷心向百奥赛图和联席保荐人表示祝贺。”

史密夫斐尔已经为众多生物科技公司在香港上市提供法律服务,包括润迈德医疗(02297.HK)、乐普生物(02157.HK)、百心安(02185.HK)、和誉开曼(02256.HK)、先瑞达医疗(06669.HK)、心玮医疗(06609.HK)、腾盛博药(02137.HK)、科济药业(02171.HK)、德琪医药(06996.HK)、沛嘉医疗(09996.HK)、中国抗体(03681.HK)、东曜药业(01875.HK)和君实生物(01877.HK)。

科伟史密夫斐尔联营办公室合伙人谢守德(Stanley Xie)表示:“我们在为寻求海外上市的中国公司提供咨询方面保持着优秀记录,期待继续为发行人和保荐人就融资活动提供支持。”

史密夫斐尔香港办公室合伙人(高级注册外国律师)孔瑾(Jin Kong)表示:“我们的资本市场业务满足了多个行业和司法管辖区的客户需求。在过去三年里,我们已经为二十多家来自医疗保健、TMT和制造业的中国公司就其在香港和在其他市场上市提供法律服务。”

合伙人艾迈修、谢守德和孔瑾率领律师团队为此次上市的联席保荐人提供法律服务。主要团队成员包括方靖颐(Senior Associate)、王令轩(Associate)、李天恩(Associate)、季晓源(Associate)、陈海韵(Associate)、王婷(Associate)和叶晗(Legal Assistant)。资深顾问林苡萱(注册外国律师)、种欢子(Legal Manager)、洪从译(Trainee Solicitor)、卢嘉铮(Legal Assistant)和陈可宜 (Legal Assistant)也提供了支持。

金燊(Legal Manager)率领的科伟史密夫斐尔联营办公室替代性法律服务(ALT)联合团队在上市项目期间为招股书验证及其他文件密集型工作提供高效率的解决方案。周雅菁(Senior Legal Analyst)提供支持。

Key contacts

Matthew Emsley photo

Matthew Emsley

Managing Partner, China, Hong Kong

Matthew Emsley
Stanley Xie photo

Stanley Xie

, Hong Kong

Stanley Xie
Jin Kong photo

Jin Kong

Senior Foreign Registered Lawyer (USA – New York), Hong Kong

Jin Kong

Media contact

For further information on this article please contact

Sally Greig

Head of Communications, Asia

Hong Kong

Media contact

For further information on this article please contact

Vivian Huang

Communications Manager, China

Beijing